EMPIRE STATE BUILDING, NEW YORK, NY
Annual Report to Security Holders
IN8bio Reports 2025 Results - Survival Improvements in Glioblastoma
Director Resignation - Alan S. Roemer Steps Down from Board
Kate Rochlin Appointed President of IN8bio, Inc. Effective February 4, 2026
IN8bio, Inc. Enters Securities Purchase Agreement for Common Stock
Other Events
Results of Operations and Financial Condition
Presents T Cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications
FY 2025
Q3
Q2
Q1
Amended Annual Report
FY 2024
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Schedule 13D - Ownership Report
Definitive Revised Proxy Statement